Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers RARE said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2027
Given $100.00M to $110.00M release Feb 12, 2026
– Not reported yet
The company's words
Dojolvi revenue in the range of $100 million to $110 million 3 Strategic restructuring plan and path to profitability in 2027 release Feb 12, 2026
Revenue
Fiscal 2026
Given $500.00M to $520.00M release Feb 12, 2026
Raised $730.00M to $760.00M release May 5, 2026
Kept $730.00M to $760.00M release Aug 4, 2026
Kept $730.00M to $760.00M release Nov 3, 2026
– Not reported yet
The company's words
Financial Guidance and Strategic Restructuring Plan 2026 revenue guidance … Crysvita revenue in the range of $500 million to $520 million , reflecting growing underlying global demand partially offset by expected timing of ordering patterns in Brazil release Feb 12, 2026
The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches. release May 5, 2026
The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches. release Aug 4, 2026
The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches. release Nov 3, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $640.00M to $670.00M release Jan 13, 2025
Kept $640.00M to $670.00M release Feb 13, 2025
Kept $640.00M to $670.00M release May 6, 2025
Kept $640.00M to $670.00M release Aug 5, 2025
Kept $640.00M to $670.00M release Nov 4, 2025
$673.00M
10-K filed 2026-02-18
Above the range
The company's words
2025 expected total revenue guidance of $640 million to $670 million release Jan 13, 2025
2025 Financial Guidance … Total revenue to be in the range of $640 million to $670 million release Feb 13, 2025
Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release May 6, 2025
Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release Aug 5, 2025
Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release Nov 4, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $500.00M to $530.00M release Jan 8, 2024
Kept $500.00M to $530.00M release Feb 15, 2024
Kept $500.00M to $530.00M release May 2, 2024
Raised $530.00M to $550.00M release Nov 5, 2024
$560.23M
10-K filed 2025-02-19
Above the range
The company's words
2024 expected Total Revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release Jan 8, 2024
2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release Feb 15, 2024
Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release May 2, 2024
Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million release Nov 5, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.